Contact

Please use this form to send email to PR contact of this press release:
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP

TO:

FROM:
Your Name:
Your Email:	Please check your email address!
Subject:
Message:
Confirmation code:	Please, do not fill this field.
Confirmation version code:	Please, do not change this field.
Javascript data:	Please, do not fill if your javascript is turned off.
Please type in the code you see in the image. Or click Send Email to generate another image instead.
	SEND EMAIL